Valiant Organics Limited · NSE:VALIANTORG
Valiant Organics — Q4 FY2024-25 Earnings Presentation
28 slides from Valiant Organics's earnings presentation, Jul 1, 2025
Slide 1: Investor Presentation Intimation Letter to Exchanges
July 01, 2025 To, To, Listing / Compliance Department Listing / Compliance Department BSE LTD National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1, Dalal Street G Block Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E), Mumbai- 400 051. SCRIP CODE – 540145 S
Slide 2: Investor Presentation | June 2025
Investor Presentation | June 2025 1
Slide 3: Snapshot
SNAPSHOT One of the largest chlorophenol One of the leading manufacturer of derivatives manufacturer globally Benzene derivatives products One of the largest domestic PNA One of the few commercial players in manufacturer Ortho Anisidine and Para Anisidine Diversified client base across Amongst 1st f
Slide 4: Company Overview
eeee Valiant 01 9000 COMPANY OVERVIEW
Slide 5: Company Overview
Company Overview Valiant Organics Limited was incorporated in 1984 by first generation technocrats and is headquartered out of Mumbai, India. The company is focused on the manufacturing and marketing of specialty chemicals which find usage in a variety of industries, including agrochemicals, pharmac
Slide 6: Board of Directors
Board of Directors Shri Navin C. Shah Shri Mahek M. Chheda (Chairman & Independent Shri Sathiababu K. Kallada (Executive Director & Director) (Managing Director) Chief Financial Officer ) Shri Nemin Savadia Shri Siddharth Shah Shri Parimal H. Desai (Executive Director) (Executive Director) (Managing
Slide 7: Key Milestones
Key Milestones Emerged as a major supplier of Chlorophenols in India and the Expanded product range global markets. Acquired Amarjyot Listed on the NSE in to include Chlorophenols, Chemicals, a large specialised July. Completed Phase Achieved ramp up for usage in intermediates chemical maker and sup
Slide 8: Manufacturing Footprint
Manufacturing Footprint CHLORINATION – SARIGAM HYDROGENATION & METHOXYLATION- • Capacity: 18,000 MTPA JHAGADIA UNIT 1 • Products: PCP, OCP, 2,4 DCP, 2,6 DCP, • Capacity: 27,000 MTPA 2,4,6 TCP • Products: ONA/OA, PNA/PA, IPPCA, CONVERSION PRODUCTS AMMONOLYSIS - VAPI HYDROGENATION – JHAGADIA UNIT 2 •
Slide 9: Key Strengths
Key Strengths Domain expertise and broad Plant locations are process understanding in a Wide supply chain strategically located near variety of chemistries. The provides the continuous ports to provide a executive team is made up of availability of adequate competitive advantage, first-generation te
Slide 10: Capex Projects
Capex Projects Product Project Status Remarks Ongoing Projects • Currently, entirely imported in India Ortho Amino Phenol (OAP) Expected to commence • Part of the production will be utilized as forward integration for one of company's existing products • Trial run successful however, further improve
Slide 11: Business Overview
seco Valiant Organics Limited 9000 BUSINESS OVERVIEW
Slide 12: Chemistries And Product Basket
Chemistries And Product Basket FY25 Revenue Share Hydrogenation Ammonolysi 47% Key Products: s Key Products: • Ortho Anisidine Industries Industries Served: Served: • Para Nitro Aniline • Para Anisidine • Dyes • Dyes • Ortho Chloro Para Nitro • IPPCA • Pigments • Pigments Aniline • Meta Chloro Anili
Slide 13: Chlorination
Chlorination Any reaction in which chlorine or chlorine compounds are introduced into a molecule to obtain the Revenues (INR Mn)* desired outcome is known as chlorination. 3,000 2,765 • Valiant is the only domestic player and also a global leader in Chlorophenol products with ~25% global 2,500 marke
Slide 14: Ammonolysis
Ammonolysis Ammonolysis is a high-pressure chemical reaction done in an auto clave where ammonia is Revenues (INR Mn)* used as a reactant. 3,500 2,917 • Valiant developed Ammonolysis capabilities as a result of its two acquisitions. i.e. Abhilasha Tex 3,000 2,666 Chem Pvt. Ltd. in 2017 & Amarjyot Ch
Slide 15: Hydrogenation
Hydrogenation Hydrogenation is a chemical reaction between molecular hydrogen (H2) and another compound or element, usually in the presence of a catalyst. Revenues (INR Mn)* • The company has manufacturing facilities in Jhagadia for Hydrogenation. The first unit (also named 5,000 4,331 as Unit 1) ha
Slide 16: Other Processes
Other Processes Acetylation Revenues (INR Mn)* Acetylation is a chemical reaction which introduces an acetyl functional group into a chemical 855 compound. 900 800 • The acetylation procedure is carried out at the company’s Ahmedabad facility which has a capacity of 700 564 1,800 MTPA 600 500 441 37
Slide 17: Industry Overview
seco Valiant Organics Limited 9000 INDUSTRY OVERVIEW
Slide 18: Industry Overview
Industry Overview • Expansive Product Portfolio: India's chemical landscape is vast, boasting over 80,000 commercial products, offering a diverse array of solutions to global demands. Global Chemical Market (USD Bn) • Global Manufacturing Powerhouse: Positioned as the 6th largest manufacturer of che
Slide 19: Advantage India: Key Growth Factors
Key Growth Factors GROWING POLICY INCREASING ADVANTAGE INDIA OPPORTUNITIES DEMAND SUPPORT INVESTMENT • Rise in demand from end-users • Supply disruption in China has • The government plans to Industries such as food processing, caused the global end-user • FDI inflows amounting to USD implement a pr
Slide 20: Financial Overview
seco Valiant Organics Limited 2000 FINANCIAL OVERVIEW
Slide 21: Historical Consolidated Income Statement
Historical Consolidated Income Statement Particulars (INR Mn) FY22 FY23 FY24 FY25 Revenue from Operations 11,533 10,518 7,231 7,188 Total Expenses 9,484 8,875 6,849 6,651 EBITDA 2,049 1,643 382 537 EBITDA Margins (%) 17.77% 15.62% 5.28% 7.47% Other Income 74 80 93 86 Depreciation 296 292 349 358 Fin
Slide 22: Consolidated Balance Sheet
Consolidated Balance Sheet Particulars (INR Mn) FY23 FY24 FY25 Particulars (INR Mn) FY23 FY24 FY25 EQUITY 7,401 7,293 7,253 Non-Current Assets 7,682 8,352 8,269 a) Equity Share Capital 272 276 280 a) Property, Plant and Equipment 6,565 6,297 6,437 b) Other Equity 6,616 7,017 6,973 c) Right-Of-Use As
Slide 23: Historical Standalone Income Statement
Historical Standalone Income Statement Particulars (INR Mn) FY22 FY23 FY24 FY25 Revenue from Operations 9,484 9,116 6,772 7,188 Total Expenses 7,811 7,817 6,376 6,651 EBITDA 1,673 1,299 396 537 EBITDA Margins (%) 17.64% 14.25% 5.85% 7.47% Other Income 33 29 29 81 Depreciation 273 276 340 358 Finance
Slide 24: Standalone Balance Sheet
Standalone Balance Sheet Particulars (INR Mn) FY23 FY24 FY25 Particulars (INR Mn) FY23 FY24 FY25 EQUITY 6,661 6,649 6,616 Non-Current Assets 7,424 7,818 7,750 a) Equity Share Capital 272 276 280 a) Property, Plant and Equipment 6,092 6,297 6,437 b) Other Equity 6,385 6,373 6,336 b) Right-Of-Use Asse
Slide 25: Consolidated Financial Highlights
Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 11,533 1,279 2,049 1,400 10,518 10,000 1,643 1,100 1,026 7,500 7,231 7,188 800 5,000 537 500 17.77% 15.62% 382 2,500 5.28% 200 11.09% 9.75% -34 7.47% -84 - -100 FY22 FY2
Slide 26: Capital Market Information
Capital Market Information Share Price up to 31st March, 2025 30% 10% -10% -30% -50% -70% Apr-24 May-24 Jun-24 Jul-24 Aug-24 Sep-24 Oct-24 Nov-24 Dec-24 Jan-25 Feb-25 Mar-25 Valiant Organics Sensex Price Data (As of 31st March, 2025) INR Shareholding pattern (As of 31st March, 2025) FII; 0.37% DII;
Slide 27: Disclaimer
Disclaimer Valiant Organics Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all event
Slide 28: Thank You
eeee Valiant 01 9000 THANK YOU
Valiant Organics — Q4 FY2024-25 Earnings Presentation on 6ix